PP 5.4 – 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents

• L. Pache,
• J. Kim,
• M. Marsden,
• F. Layng,
• A. Limpert,
• D. Heimann,
• W. Thienphrapa,
• N. Cosford,
• J. Zack,
• S. Chanda

Affiliations

L. Pache

Infectious and Inflammatory Disease Center, Immunity and Pathogenesis Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA

J. Kim

Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA

M. Marsden

Department of Microbiology and Molecular Genetics and Department of Medicine, Division of Infectious Diseases, School of Medicine, University of California, Irvine, CA 92697, USA

F. Layng

Cell Metabolism and Signaling Networks Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA

A. Limpert

Cell Metabolism and Signaling Networks Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA

D. Heimann

Cell Metabolism and Signaling Networks Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA

W. Thienphrapa

Infectious and Inflammatory Disease Center, Immunity and Pathogenesis Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA

N. Cosford

Cell Metabolism and Signaling Networks Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA

J. Zack

Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA

S. Chanda

Department of Immunology and Microbiology, Scripps Research, La Jolla, CA 92037, USA